These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21432415)

  • 1. Cigarette smoking is associated with the reduction of lymphokine-activated killer cell and natural killer cell activities.
    Inoue C; Takeshita T; Kondo H; Morimoto K
    Environ Health Prev Med; 1996 Apr; 1(1):14-9. PubMed ID: 21432415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifestyles and mental health status are associated with natural killer cell and lymphokine-activated killer cell activities.
    Morimoto K; Takeshita T; Inoue-Sakurai C; Maruyama S
    Sci Total Environ; 2001 Apr; 270(1-3):3-11. PubMed ID: 11327395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
    Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
    Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission.
    Adler A; Chervenick PA; Whiteside TL; Lotzová E; Herberman RB
    Blood; 1988 Mar; 71(3):709-16. PubMed ID: 3257887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer (NK) and lymphokine-activated killer (LAK) activities in a patient who recovered from cancer, and the characteristics of LAK cells generated from CD4-CD8- and CD8+ peripheral blood lymphocytes.
    Komatsu F; Kihara K
    Clin Immunol Immunopathol; 1995 Oct; 77(1):75-81. PubMed ID: 7554487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
    Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
    Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible inhibition of lymphokine-activated killer cell activity by lipoxygenase-pathway inhibitors.
    Sibbitt WL; Imir T; Bankhurst AD
    Int J Cancer; 1986 Oct; 38(4):517-21. PubMed ID: 3019899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer, lymphokine-activated killer and interferon-gamma producing activities of peripheral blood- and regional lymph node-mononuclear cells in 23 cases of colorectal cancer.
    Matsunaga H; Kuwahara Y; Kusugami K; Morise K; Shimokata K
    Gastroenterol Jpn; 1988 Oct; 23(5):527-33. PubMed ID: 3145895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
    Miller JS; Verfaillie C; McGlave P
    Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic and functional differences in NK and LAK cells in the peripheral blood of sooty mangabeys and rhesus macaques.
    Powell JD; McClure HM; Anderson D; Fultz PN; Sell KW; Ahmed-Ansari A
    Cell Immunol; 1989 Nov; 124(1):107-18. PubMed ID: 2553275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition.
    Mueller EA; Anderer FA
    Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assay of lymphokine-activated killer activity generated from bone marrow cells of children with acute lymphoblastic leukemia.
    Zhou MX; Findley HW; Davis R; Ragab AH
    Blood; 1990 Jan; 75(1):160-5. PubMed ID: 2294987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
    Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cytolytic activity by lymphokines (LAK activity) in chronic myeloid leukemia].
    Cervantes F; Miller JS; McGlave PB
    Med Clin (Barc); 1995 Jun; 105(2):50-3. PubMed ID: 7603094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phenotypical analysis of effector cells on nonspecific cancer cell therapy].
    Sudo T; Kobayashi Y; Matsushita N; Shimizu K; Nakao M; Tanaka Y; Tanigawa K; Aruga A
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1817-20. PubMed ID: 14619528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells.
    Manning LS; Bowman RV; Darby SB; Robinson BW
    Am Rev Respir Dis; 1989 Jun; 139(6):1369-74. PubMed ID: 2786360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation of human NK cells and generation of LAK activity.
    Whiteside TL
    Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.7. PubMed ID: 18432847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human pulmonary natural killer (NK) cells exhibit limited lymphokine-activated killer (LAK) activity.
    Yarbrough WC; Weissler JC
    Am J Respir Cell Mol Biol; 1989 Oct; 1(4):305-11. PubMed ID: 2483121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing.
    Atzpodien J; Gulati SC; Shimazaki C; Bührer C; Oz S; Kwon JH; Kolitz JE; Clarkson BD
    Oncology; 1988; 45(6):437-43. PubMed ID: 3263598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.